Compass Therapeutics (CMPX) Enterprise Value (2021 - 2026)

Compass Therapeutics has reported Enterprise Value for 9 years, with the latest figure at -$194.7 million in Q1 2026.

• Quarterly Enterprise Value fell 72.85% year-over-year to -$194.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$194.7 million (down 72.85% YoY) and the FY2025 annual result came in at -$209.5 million, down 64.56% from the prior year.
• Enterprise Value improved to -$194.7 million in Q1 2026 per CMPX's latest filing, from -$209.5 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$100.9 million in Q2 2025 and troughed at -$219.9 million in Q3 2025.
• A 5-year average of -$154.2 million and a median of -$152.5 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 372.78% in 2022, then jumped 30.96% in 2025.
• Over 5 years, Enterprise Value stood at -$186.6 million in 2022, then advanced by 18.28% to -$152.5 million in 2023, then climbed by 16.51% to -$127.3 million in 2024, then plunged by 64.56% to -$209.5 million in 2025, then advanced by 7.06% to -$194.7 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$194.7 million, -$209.5 million, and -$219.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.